WO1999015105A1 - Non-thrombogenic stent jacket - Google Patents

Non-thrombogenic stent jacket Download PDF

Info

Publication number
WO1999015105A1
WO1999015105A1 PCT/IB1998/001459 IB9801459W WO9915105A1 WO 1999015105 A1 WO1999015105 A1 WO 1999015105A1 IB 9801459 W IB9801459 W IB 9801459W WO 9915105 A1 WO9915105 A1 WO 9915105A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
expandable
jacket
cylindrical jacket
delivery catheter
Prior art date
Application number
PCT/IB1998/001459
Other languages
French (fr)
Inventor
Carlos Vonderwalde Freidberg
Original Assignee
Carlos Vonderwalde Freidberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/935,784 external-priority patent/US6468300B1/en
Application filed by Carlos Vonderwalde Freidberg filed Critical Carlos Vonderwalde Freidberg
Priority to JP2000512482A priority Critical patent/JP2003526380A/en
Priority to AU90911/98A priority patent/AU749285B2/en
Priority to CA002304495A priority patent/CA2304495C/en
Priority to DE69840652T priority patent/DE69840652D1/en
Priority to ES98942952T priority patent/ES2323741T3/en
Priority to EP98942952A priority patent/EP1017335B1/en
Publication of WO1999015105A1 publication Critical patent/WO1999015105A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/062Apparatus for the production of blood vessels made from natural tissue or with layers of living cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/075Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/901Method of manufacturing prosthetic device

Definitions

  • stents are expandable, tubular metallic devices that are positioned within a patient's vasculature or other body lumen and expanded in order to support a vessel or body lumen at a desired intraluminal location to allow the flow of blood or other body fluids therethrough.
  • the stents are formed from a deformable metal and delivered to the desired intraluminal location by mounting the stent onto an expandable portion, e.g. a balloon, on the distal extremity of a delivery catheter.
  • the stent By advancing the catheter through the body lumen, the stent may be delivered to a desired position and expanded therein by expanding the expandable member, e.g. the balloon to an expanded configuration, seating it within the artery or other body lumen.
  • the expandable member e.g. the balloon
  • an expanded configuration seating it within the artery or other body lumen.
  • Other implementations make use of a self-expanding stent formed from a suitable material such as pseudoelastic material that is delivered in a constricted condition and when released spontaneously expands to an enlarged configuration.
  • a stent made of shape memory alloy e.g. NiTi alloy
  • NiTi alloy may be inserted into the body lumen in a martensitic phase and transformed to an austenite phase which has an expanded memory when raised to a temperature above the transformation temperature, usually less than 45 °C.
  • Stents are often used in conjunction with an intravascular treatment for obstructive coronary artery disease.
  • ablation, atherectomy, balloon dilation, laser treatment or other procedures are among the methods used to widen a stenotic region of a patient's vasculature.
  • restenosis occurs in large percentage of percutaneous transluminal coronary angioplasty (PTCA) patients and rates can be even higher with other procedures.
  • PTCA percutaneous transluminal coronary angioplasty
  • the prior art has employed a number of mechanical and pharmacological strategies to reduce the restenosis rate, but none have been particularly effective.
  • stents have been proposed to maintain the patency of a treated vessel and prevent restenosis. Using stents, restenosis rates have fallen to less than 20%.
  • Restenosis is thought to be a natural healing reaction provoked by injury from the intravascular procedure. The healing process frequently causes thrombosis and may lead to intimal hyperplasia that occludes the vessel.
  • stents do not represent a complete solution. The framework of the stent may still allow migration and proliferation of the smooth muscle cells, while the stent itself can be thrombogenic.
  • stents have been covered with DACRON, PTFE and autologous vein and the stent surface has been seeded with endothelial cells or otherwise treated.
  • the invention is directed to a stent assembly suitable for maintaining the patency of a bodily lumen, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue disposed about the exterior of the expandable stent.
  • the heterologous tissue is selected from the group consisting of bovine pericardium, porcine pericardium, aortic leaflet and other suitable heterologous tissue.
  • the stent may be an expandable, tubular framework and may be a conventional self expanding or balloon expandable stent.
  • the jacket is disposed about either or both of the outer and inner surfaces of the stent. In a preferred embodiment, the jacket is generally cylindrical for corresponding to the tubular framework or the stent.
  • This invention is also directed to a method for maintaining the patency of a bodily lumen generally comprising providing a delivery catheter having an expandable member on the distal extremity thereof, mounting the stent assembly, including a tubular stent with a jacket of biocompatible, non- thrombogenic expandable material such as heterologous tissue disposed about at least part of the stent, on the expandable member on the distal extremity of the delivery catheter.
  • the catheter is advanced through the body lumen within the patient until the distal extremity of the catheter having the stent assembly is positioned at a desired location therein.
  • the stent assembly is expanded by expanding the expandable member onto which the stent assembly is mounted to anchor the stent assembly within the body lumen. Once the stent assembly is effectively positioned within the body lumen, the expanded expandable member may be contracted, e.g. by deflating the balloon, and then the delivery catheter may be withdrawn.
  • a presently preferred embodiment of the invention is directed to a stent assembly suitable for expansion within a body lumen and delivery of a therapeutic or diagnostic agent therein, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue, which contains the therapeutic or diagnostic agent and which is disposed about the expandable stent.
  • the jacket releasably contains at least one therapeutic or diagnostic agent.
  • therapeutic or diagnostic agents for a variety of indications can be used, including angiogenesis agents and antithrombotic agents.
  • antithrombotic agents is meant to include various agents for reducing the risk of thrombosis, including anticoagulants such as heparin, thrombolytic agents such as urokinase, streptokinase, tissue plasminogen activator (ACTILYSE), monoclonal antibodies such as abciximab (REOPRO), fibrinolytic agents, and the like.
  • Angiogenesis agents that stimulate the growth of neo-vessels include agents such as basic Fibroblast Growth Factor (bFGF) and Vascular Endothelial Growth Factor (VEGF).
  • the jacket is impregnated with a liquid containing the therapeutic or diagnostic agent.
  • a liquid containing the therapeutic or diagnostic agent for example, a jacket formed from heterologous tissue which is submerged in a solution of the therapeutic agent will absorb the solution.
  • a variety of suitable methods of applying the agent to the jacket may be used, including using electrodeposition, heat and pressure.
  • the stent assembly can be positioned at a desired site within the patient's body lumen, where the jacket will release the therapeutic agent.
  • the jacket on the stent assembly may be impregnated just before use, or alternatively, stored in the therapeutic or diagnostic agent so that the stent assembly is preimpregnated.
  • the invention is also directed to a method for delivery of a therapeutic or diagnostic agent within a body lumen.
  • the stent assembly including a tubular stent with a jacket of biocompatible, non-thrombogenic expandable material, such as heterologous tissue, containing a therapeutic or diagnostic agent is positioned within the body lumen as outlined above. With the stent assembly positioned at a desired location, the therapeutic or diagnostic agent is released from the jacket into the body lumen and thereby delivered at and around the location of the stent assembly within the body lumen.
  • the expanded jacket of biocompatible, non-thrombogenic expandable material such as heterologous tissue should extend over a substantial portion, preferably all, of the stenotic region in which it is disposed in order to minimize the restenosis.
  • Figure 1 is a perspective view, partially broken away, of a stent assembly of the invention showing a tubular, expandable stent with an expandable biocompatible non-thrombogenic cylindrical exterior jacket.
  • Figure 2 is an elevational view, partially in section, of a delivery catheter having a jacketed stent mounted on an inflatable balloon on the distal extremity of the catheter.
  • Figure 3 is a transverse cross sectional view of the stent assembly shown in Figure 1 , taken along lines 3-3.
  • Figure 4 is a perspective view, partially in section, of one embodiment of the stent assembly, shown in the expanded configuration, having a biocompatible non-thrombogenic jacket covering the length of the expandable stent.
  • Figure 5 is a transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non- thrombogenic jacket in a S-shaped folded configuration.
  • Figure 6 is a transverse cross sectional view of another embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non- thrombogenic jacket in a U-shaped folded configuration.
  • Figure 7 is a perspective view, partially broken away, of one embodiment of the stent assembly having a biocompatible non-thrombogenic jacket comprising an overlapping ribbon.
  • Figure 8 is transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, having a biocompatible non- thrombogenic jacket in an overlapping wrapped configuration.
  • stent assembly 1 0 comprises a tubular, expandable metallic framework forming the stent 1 2 with an exterior jacket 14 of heterologous tissue.
  • metallic stent 1 2 extends about 1 mm beyond each end of jacket 1 4 to prevent prolapse of the tissue into the lumen of the stent when it is expanded.
  • Jacket 1 4 may be secured to metallic framework 1 2 by any suitable means. For example, four radially spaced sutures 1 6 may be placed at each end of jacket 14.
  • the jacket 1 4 contains a therapeutic or diagnostic agent, as shown in Fig. 3, illustrating a transverse cross section of the stent assembly shown in Fig. 1 , taken along lines, 3-3.
  • Exterior jacket 1 4 preferably comprises bovine pericardium, a material shown to resist suture line bleeding, require no pre-clotting, support endothelialization and have an excellent host-tissue response.
  • bovine pericardial tissue has an elasticity of up to about 30% which allows the tissue cylinder to conform to both the unexpanded and expanded configurations of the stent 1 2 with out adding a great deal of bulk which increases the profile on the balloon.
  • Other heterologous tissue suitable in the practice of the invention includes porcine pericardium, aortic leaflet, veins and arteries, and others. Useful heterologous tissue is relatively impervious and impenetrable so as to prevent tissue build up and the migration of smooth muscle cells through the stent framework.
  • a particularly preferred bovine pericardium has cross-linked collagen and is available from Bio Vascular. Bovine pericardium tissue is available in a thickness ranging from about 0.25 mm to about 0.75 mm, with an average of about 0.45 mm.
  • the biocompatible non-thrombogenic jacket 1 4 has a thickness of less than about 0.25 mm, and preferably has a thickness of about 0.05 mm to about 0.20 mm, and most preferably about 0.1 mm to about 0.1 5 mm.
  • biocompatible non- thrombogenic jackets having a thickness of up to about 0.75 mm may be used.
  • the heterologous tissue used to form the jacket is typically thinned before being assembled with the stent. The tissue may be thinned by a variety of suitable methods including peeling, shaving or otherwise removing a thin layer of the tissue.
  • the thin jacket comprises the serous pericardium, which is the smooth, inner layer of the pericardium, which has been separated from at least a part of the outer layer of the pericardium.
  • the venous or arterial walls may be thinned to the presently preferred thickness of about 0.05 mm to about 0.20 mm.
  • the jacket may have reduced elasticity, so that the thin jacket is preferably provided on the unexpanded stent in a folded or overlapping wrapped configuration which provides sufficient material to cover the larger circumference of the expanded stent, as will be discussed in greater detail below.
  • the biocompatible non-thrombogenic jacket 1 4 preferably has a length configured to cover the length of the expanded stent, as illustrated in Fig. 4, showing an expanded stent 1 2 with a jacket 1 4 extending the length of the stent, with a length equal to the stent length.
  • the jacket may have a length that is not equal to the length of the stent.
  • the jacket may have a length less than the stent length, as illustrated in Fig. 1 , preferably not more than about 10%-20% less than the length of the stent.
  • the jacket may cover an even smaller percentage of the length of the stent, as for example, when the stent assembly is used in a Transjugular Intrahepatic Portal Shunt (TIPS) application, where the jacket length is about 50% less than the length of the stent.
  • the jacket may have a length greater than the length of the stent, preferably not more than about 5% greater than the stent length.
  • the jacket preferably has a circumference about equal to the circumference of the expanded stent, configured to fit on an inner or outer surface of the expanded stent.
  • the jacket preferably fits on the expanded stent so that the jacket conforms to the expanded stent without flaps of excess material.
  • Metallic stent 1 2 may comprise any suitable conventional stent.
  • Micro Stent II and GFX stents available from Arterial Vascular Engineering, and Multi-Link, available from Guidant have proven useful.
  • Other stents that may be used in the practice of this invention include the Palmaz- Shatz stent from Johnson and Johnson, the Gianturco stent from Cook Incorporated and other commercially available stents.
  • Conventional balloon expandable stents are preferred, but, as previously mentioned, self-expanding stents, such as those formed from shape memory materials, are also suitable.
  • the stent assembly is formed by covering a surface of the unexpanded stent with the heterologous tissue forming the jacket 14.
  • the heterologous tissue is mounted onto the unexpanded stent in the form of a cylinder of tissue.
  • the cylinder of heterologous tissue forming the jacket 14 may be formed by cutting a rectangle of tissue having a length about 2 mm shorter than the stent on which it is to be mounted and a width about equal to the circumference of the expanded stent.
  • the two sides corresponding to the length of the stent then may be secured together, such as by sewing with 6-0, 7-0, 8-0 or 1 0-0 polypropylene sutures.
  • Other means for securing the sides of the stent cover together include mechanical means such as staples, adhesive or chemical bonding and the like. It may be desirable to support the tissue while manipulating it.
  • a 9 French introducer dilator may be used to support a 3 mm diameter cylinder, an 1 1 French dilator for a 3.5 mm cylinder and a 1 2 French dilator for a 4 mm cylinder.
  • the cylinder of tissue having a circumference about equal to the circumference of the expanded stent may be provided on the unexpanded stent in a folded or wrapped configuration.
  • the tissue on the unexpanded stent forms wings 30 on either side of the stent which are folded about stent, reducing the profile of the assembly, and unfolding upon expansion of the stent.
  • the wings are folded in the same direction in an S-shaped configuration.
  • the wings of the cylinder of tissue on the unexpanded stent are folded about stent in opposite directions in a U-shaped configuration.
  • the cylinder of tissue may be placed about the unexpanded stent in a variety of suitable configurations, as for example, where the wings of the cylinder of tissue are collapsed toward the stent, such as in an accordion type configuration (not shown).
  • the heterologous tissue forming the jacket could be folded about the unexpanded stent as outlined above whether or not the tissue had been formed into a cylinder of tissue before mounting onto the unexpanded stent.
  • the heterologous tissue is wrapped around the unexpanded stent, so that sufficient tissue to cover the expanded stent is provided.
  • a ribbon of tissue is spirally wrapped around the unexpanded stent down a length thereof. The adjacent turns of the ribbon of tissue overlap, so that the ribbon unwraps as the stent expands to provide the jacket 1 4 configured to cover the expanded stent and having a circumference about equal to the circumference of the expanded stent.
  • the ribbon of tissue is wrapped along the entire length of the stent.
  • a rectangle of tissue having a width about equal to the circumference of the expanded stent on which it is to be mounted is repeatably wrapped around the outer circumference of the unexpanded stent, so that multiple layers of tissue are present on at least a part of the unexpanded stent, as shown in Fig. 8, illustrating a transverse cross section of an unexpanded stent with a wrapped jacket thereon.
  • one end of the tissue is fixed to the stent, and the tissue is then tightly wrapped around the stent.
  • the tissue unwraps to provide the jacket 14 having a circumference about equal to the circumference of the expanded stent.
  • the length of the tissue is about equal to the length of the stent.
  • the tissue can be caused to remain in the folded or wrapped configurations until the stent is expanded by pressing the fluid out of the folded or wrapped tissue.
  • securing members such as surgical tape, ties, or breakable bands may be provided to releasably hold the tissue in the folded or wrapped configurations.
  • the tissue may be kept wet at all times during manipulation or it may be dry until advanced into the patient's blood stream. Additionally, radio-opaque markers, such as rings of gold or platinum, may be added to the outer layer of the tissue so that the integrity of the cylinder may be assured before deployment within the body lumen.
  • radio-opaque markers such as rings of gold or platinum
  • the cylinder of heterologous tissue configured to be mounted onto a stent and the jacket 14 formed by the cylinder of tissue or the unwrapped or unfolded tissue generally has a length, for coronary applications, of about 4 to greater than about 80 mm, typically about 5 to about 80 mm, preferably about 1 0 to about 50 mm, and a diameter of about 1 .5 to about 35 mm, typically about 2 to about 6 mm, preferably about 2.5 to about 5 mm.
  • the actual length and diameter of the cylinder of heterologous tissue may vary, and will depend on the nature of the vessel in which the stent assembly is implanted.
  • a larger cylinder of heterologous tissue having a length of about 5 mm to about 200 mm and a diameter of about 2 mm to about 60 mm would be used.
  • the jacketed stent assembly 10 is inserted into the body lumen in the following fashion.
  • a guidewire 20 is backloaded into a delivery catheter 22 having the jacketed stent assembly 1 0 mounted over an inflatable balloon 24 on the distal extremity of the delivery catheter (as schematically shown in Fig. 2) or on a self expanding stent delivery system (not shown).
  • the catheter 22 and guidewire 20 are percutaneously introduced by means of a conventional Seldinger technique and a 5 ⁇ 9 or 1 0 French guiding catheter (not shown) into the patient's arterial system. Larger guiding catheters, for example up to about 25 Fr, may be used depending on the application.
  • the guidewire 20 is advanced out delivery catheter 22 through the vasculature under fluoroscopic imaging until it crosses a stenotic region.
  • the catheter 22 is advanced over the guidewire 20 until the stent assembly 10 is positioned at the desired location within the stenotic region. Then, the balloon 24 is inflated or the securing mechanism of the self expanding stent is released to expand the stent 1 2 and cylindrical jacket 1 4, seating the assembly 1 0 within the vessel. The balloon 24 is then deflated and the catheter 22 is removed, leaving the expanded stent assembly 10 in place.
  • the covered stents of this invention may be used in a number of coronary artery, peripheral artery and non-vascular applications.
  • coronary artery applications include use in ectatic arteries and ectatic arteries containing an obstructive lesion, aneurismatic arteries, saphenous vein grafts and native arteries, coronary perforation, coronary fistula, and ostial coronary lesions.
  • Peripheral artery applications include aortic abdominal aneurysm and other aneurismatic peripheral arteries, transjugular intrahepatic portal shunt, percutaneous transluminal angioplasty, fistula closing and neuro interventions (such as aneurysms and arterial-venous malformations), small vessel intraluminal grafting, and ostial renal artery lesions.
  • the covered stents of this invention may be used in urological, gastroenterological, respiratory, neurological, and other non-vascular applications.
  • urological field applications include urethral stenting for stenosis due to tumors, fibrous tissue and perforation.
  • Gastroenterological field applications include fistula closing, reconstruction such as esophagus reconstruction, and esophageal bleeding.
  • Respiratory field applications include tracheal and bronchial obstructions
  • neurological field applications include carotid angioplasty.
  • the assembly may include a second expandable stent, so that the heterologous tissue layer is between two coaxially disposed stents.
  • the jacket may cover the entire stent or only a portion thereof.
  • the stent assembly may be used in branched body lumens, and positioned to block one or more of the branch lumens.

Abstract

A jacketed stent assembly comprising a tubular, expandable stent, preferably having a metallic framework, jacketed with a cylinder of biocompatible, non-thrombogenic expandable material, such as heterologous tissue, which, in a preferred embodiment, contains a therapeutic or diagnostic agent. In a preferred embodiment, the jacket of the expandable stent is formed of bovine or porcine pericardial tissue. A delivery catheter having an expandable member on its distal extremity may be used to deliver the stent assembly to a desired region in a lumen of a patient. The jacketed stent is expanded to be seated within the body lumen. Self-expanding jacketed stents are also contemplated.

Description

ΓMOΓM-THROMBOGENIC STENT JACKET
RELATED APPLICATIONS
This application is a continuation-in-part application of application Serial No. 08/935,784, filed September 23, 1 997, entitled STENT COVERED WITH HETEROLOGOUS TISSUE, and application Serial No. 09/005,972, filed January 1 2, 1 998, entitled STENT WITH A BIOCOMPATIBLE NON-THROMBOGENIC JACKET, and application Serial No. 09/035, 1 14, filed March 4, 1 998, entitled NON-THROMBOGENIC STENT JACKET CONTAINING THERAPEUTIC AGENTS, and application Serial No. 09/053,200, filed April 1 , 1 998, entitled NON- THROMBOGENIC STENT JACKET, which are incorporated herein in their entirety.
BACKGROUND OF THE INVENTION
This invention relates to the field of expandable intraluminal support devices such as stents and the like. Typically, stents are expandable, tubular metallic devices that are positioned within a patient's vasculature or other body lumen and expanded in order to support a vessel or body lumen at a desired intraluminal location to allow the flow of blood or other body fluids therethrough. Often, the stents are formed from a deformable metal and delivered to the desired intraluminal location by mounting the stent onto an expandable portion, e.g. a balloon, on the distal extremity of a delivery catheter. By advancing the catheter through the body lumen, the stent may be delivered to a desired position and expanded therein by expanding the expandable member, e.g. the balloon to an expanded configuration, seating it within the artery or other body lumen. Other implementations make use of a self-expanding stent formed from a suitable material such as pseudoelastic material that is delivered in a constricted condition and when released spontaneously expands to an enlarged configuration. In other embodiments, a stent made of shape memory alloy (e.g. NiTi alloy) may be inserted into the body lumen in a martensitic phase and transformed to an austenite phase which has an expanded memory when raised to a temperature above the transformation temperature, usually less than 45 °C. Stents are often used in conjunction with an intravascular treatment for obstructive coronary artery disease. For example, ablation, atherectomy, balloon dilation, laser treatment or other procedures are among the methods used to widen a stenotic region of a patient's vasculature. However, restenosis occurs in large percentage of percutaneous transluminal coronary angioplasty (PTCA) patients and rates can be even higher with other procedures. The prior art has employed a number of mechanical and pharmacological strategies to reduce the restenosis rate, but none have been particularly effective. Accordingly, stents have been proposed to maintain the patency of a treated vessel and prevent restenosis. Using stents, restenosis rates have fallen to less than 20%.
Restenosis is thought to be a natural healing reaction provoked by injury from the intravascular procedure. The healing process frequently causes thrombosis and may lead to intimal hyperplasia that occludes the vessel. Although helpful in reducing restenosis, stents do not represent a complete solution. The framework of the stent may still allow migration and proliferation of the smooth muscle cells, while the stent itself can be thrombogenic. To address these problems, stents have been covered with DACRON, PTFE and autologous vein and the stent surface has been seeded with endothelial cells or otherwise treated. Each of these solutions suffer from certain drawbacks, such as not being biocompatible, lacking sufficient mechanical strength, having a surface that is difficult to prepare, lack of ready availability and being thrombogenic. Antithrombotic drug regimens, in which anticoagulants and thrombolytic agents are administered during and after deployment of the stent, have also been employed to reduce the risk of thrombosis. Thus, there remains a need for a stent capable of minimizing restenosis while having a consistency similar to the native artery, a non-thrombogenic surface and sufficient mechanical strength as well as being biocompatible and readily available. This invention satisfies these and other needs.
SUMMARY OF THE INVENTION The invention is directed to a stent assembly suitable for maintaining the patency of a bodily lumen, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue disposed about the exterior of the expandable stent. Preferably, the heterologous tissue is selected from the group consisting of bovine pericardium, porcine pericardium, aortic leaflet and other suitable heterologous tissue. The stent may be an expandable, tubular framework and may be a conventional self expanding or balloon expandable stent. The jacket is disposed about either or both of the outer and inner surfaces of the stent. In a preferred embodiment, the jacket is generally cylindrical for corresponding to the tubular framework or the stent.
This invention is also directed to a method for maintaining the patency of a bodily lumen generally comprising providing a delivery catheter having an expandable member on the distal extremity thereof, mounting the stent assembly, including a tubular stent with a jacket of biocompatible, non- thrombogenic expandable material such as heterologous tissue disposed about at least part of the stent, on the expandable member on the distal extremity of the delivery catheter. The catheter is advanced through the body lumen within the patient until the distal extremity of the catheter having the stent assembly is positioned at a desired location therein. The stent assembly is expanded by expanding the expandable member onto which the stent assembly is mounted to anchor the stent assembly within the body lumen. Once the stent assembly is effectively positioned within the body lumen, the expanded expandable member may be contracted, e.g. by deflating the balloon, and then the delivery catheter may be withdrawn.
A presently preferred embodiment of the invention is directed to a stent assembly suitable for expansion within a body lumen and delivery of a therapeutic or diagnostic agent therein, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue, which contains the therapeutic or diagnostic agent and which is disposed about the expandable stent. The jacket releasably contains at least one therapeutic or diagnostic agent. A wide variety of therapeutic or diagnostic agents for a variety of indications can be used, including angiogenesis agents and antithrombotic agents. The term "antithrombotic agents" is meant to include various agents for reducing the risk of thrombosis, including anticoagulants such as heparin, thrombolytic agents such as urokinase, streptokinase, tissue plasminogen activator (ACTILYSE), monoclonal antibodies such as abciximab (REOPRO), fibrinolytic agents, and the like. Angiogenesis agents that stimulate the growth of neo-vessels include agents such as basic Fibroblast Growth Factor (bFGF) and Vascular Endothelial Growth Factor (VEGF).
In a presently preferred embodiment, the jacket is impregnated with a liquid containing the therapeutic or diagnostic agent. For example, a jacket formed from heterologous tissue which is submerged in a solution of the therapeutic agent will absorb the solution. A variety of suitable methods of applying the agent to the jacket may be used, including using electrodeposition, heat and pressure. Thereafter, the stent assembly can be positioned at a desired site within the patient's body lumen, where the jacket will release the therapeutic agent. The jacket on the stent assembly may be impregnated just before use, or alternatively, stored in the therapeutic or diagnostic agent so that the stent assembly is preimpregnated.
The invention is also directed to a method for delivery of a therapeutic or diagnostic agent within a body lumen. The stent assembly including a tubular stent with a jacket of biocompatible, non-thrombogenic expandable material, such as heterologous tissue, containing a therapeutic or diagnostic agent is positioned within the body lumen as outlined above. With the stent assembly positioned at a desired location, the therapeutic or diagnostic agent is released from the jacket into the body lumen and thereby delivered at and around the location of the stent assembly within the body lumen. The expanded jacket of biocompatible, non-thrombogenic expandable material such as heterologous tissue should extend over a substantial portion, preferably all, of the stenotic region in which it is disposed in order to minimize the restenosis.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a perspective view, partially broken away, of a stent assembly of the invention showing a tubular, expandable stent with an expandable biocompatible non-thrombogenic cylindrical exterior jacket.
Figure 2 is an elevational view, partially in section, of a delivery catheter having a jacketed stent mounted on an inflatable balloon on the distal extremity of the catheter.
Figure 3 is a transverse cross sectional view of the stent assembly shown in Figure 1 , taken along lines 3-3.
Figure 4 is a perspective view, partially in section, of one embodiment of the stent assembly, shown in the expanded configuration, having a biocompatible non-thrombogenic jacket covering the length of the expandable stent.
Figure 5 is a transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non- thrombogenic jacket in a S-shaped folded configuration.
Figure 6 is a transverse cross sectional view of another embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non- thrombogenic jacket in a U-shaped folded configuration.
Figure 7 is a perspective view, partially broken away, of one embodiment of the stent assembly having a biocompatible non-thrombogenic jacket comprising an overlapping ribbon.
Figure 8 is transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, having a biocompatible non- thrombogenic jacket in an overlapping wrapped configuration.
DETAILED DESCRIPTION OF THE INVENTION
In the embodiment of the invention shown in Fig. 1 , stent assembly 1 0 comprises a tubular, expandable metallic framework forming the stent 1 2 with an exterior jacket 14 of heterologous tissue. In the embodiment illustrated in Figure 1 , metallic stent 1 2 extends about 1 mm beyond each end of jacket 1 4 to prevent prolapse of the tissue into the lumen of the stent when it is expanded. Jacket 1 4 may be secured to metallic framework 1 2 by any suitable means. For example, four radially spaced sutures 1 6 may be placed at each end of jacket 14.
In a presently preferred embodiment of the stent assembly illustrated in Fig. 1 , the jacket 1 4 contains a therapeutic or diagnostic agent, as shown in Fig. 3, illustrating a transverse cross section of the stent assembly shown in Fig. 1 , taken along lines, 3-3.
Exterior jacket 1 4 preferably comprises bovine pericardium, a material shown to resist suture line bleeding, require no pre-clotting, support endothelialization and have an excellent host-tissue response. Further, bovine pericardial tissue has an elasticity of up to about 30% which allows the tissue cylinder to conform to both the unexpanded and expanded configurations of the stent 1 2 with out adding a great deal of bulk which increases the profile on the balloon. Other heterologous tissue suitable in the practice of the invention includes porcine pericardium, aortic leaflet, veins and arteries, and others. Useful heterologous tissue is relatively impervious and impenetrable so as to prevent tissue build up and the migration of smooth muscle cells through the stent framework. A particularly preferred bovine pericardium has cross-linked collagen and is available from Bio Vascular. Bovine pericardium tissue is available in a thickness ranging from about 0.25 mm to about 0.75 mm, with an average of about 0.45 mm.
In a presently preferred embodiment of the invention, the biocompatible non-thrombogenic jacket 1 4 has a thickness of less than about 0.25 mm, and preferably has a thickness of about 0.05 mm to about 0.20 mm, and most preferably about 0.1 mm to about 0.1 5 mm. However, biocompatible non- thrombogenic jackets having a thickness of up to about 0.75 mm may be used. In the embodiment of the invention in which a thin biocompatible non- thrombogenic jacket having a thickness of less than about 0.25 mm is used, the heterologous tissue used to form the jacket is typically thinned before being assembled with the stent. The tissue may be thinned by a variety of suitable methods including peeling, shaving or otherwise removing a thin layer of the tissue. In a presently preferred embodiment, the thin jacket comprises the serous pericardium, which is the smooth, inner layer of the pericardium, which has been separated from at least a part of the outer layer of the pericardium. Similarly, where other forms of heterologous tissue are used, such as veins or arteries, the venous or arterial walls may be thinned to the presently preferred thickness of about 0.05 mm to about 0.20 mm. As a result of being thinned, the jacket may have reduced elasticity, so that the thin jacket is preferably provided on the unexpanded stent in a folded or overlapping wrapped configuration which provides sufficient material to cover the larger circumference of the expanded stent, as will be discussed in greater detail below. The biocompatible non-thrombogenic jacket 1 4 preferably has a length configured to cover the length of the expanded stent, as illustrated in Fig. 4, showing an expanded stent 1 2 with a jacket 1 4 extending the length of the stent, with a length equal to the stent length. However, the jacket may have a length that is not equal to the length of the stent. For example, the jacket may have a length less than the stent length, as illustrated in Fig. 1 , preferably not more than about 10%-20% less than the length of the stent. However, the jacket may cover an even smaller percentage of the length of the stent, as for example, when the stent assembly is used in a Transjugular Intrahepatic Portal Shunt (TIPS) application, where the jacket length is about 50% less than the length of the stent. Alternatively, the jacket may have a length greater than the length of the stent, preferably not more than about 5% greater than the stent length. The jacket preferably has a circumference about equal to the circumference of the expanded stent, configured to fit on an inner or outer surface of the expanded stent. The jacket preferably fits on the expanded stent so that the jacket conforms to the expanded stent without flaps of excess material.
Metallic stent 1 2 may comprise any suitable conventional stent. For example, Micro Stent II and GFX stents available from Arterial Vascular Engineering, and Multi-Link, available from Guidant, have proven useful. Other stents that may be used in the practice of this invention include the Palmaz- Shatz stent from Johnson and Johnson, the Gianturco stent from Cook Incorporated and other commercially available stents. Conventional balloon expandable stents are preferred, but, as previously mentioned, self-expanding stents, such as those formed from shape memory materials, are also suitable. The stent assembly is formed by covering a surface of the unexpanded stent with the heterologous tissue forming the jacket 14. In one embodiment, the heterologous tissue is mounted onto the unexpanded stent in the form of a cylinder of tissue. The cylinder of heterologous tissue forming the jacket 14, may be formed by cutting a rectangle of tissue having a length about 2 mm shorter than the stent on which it is to be mounted and a width about equal to the circumference of the expanded stent. The two sides corresponding to the length of the stent then may be secured together, such as by sewing with 6-0, 7-0, 8-0 or 1 0-0 polypropylene sutures. Other means for securing the sides of the stent cover together include mechanical means such as staples, adhesive or chemical bonding and the like. It may be desirable to support the tissue while manipulating it. For example, a 9 French introducer dilator may be used to support a 3 mm diameter cylinder, an 1 1 French dilator for a 3.5 mm cylinder and a 1 2 French dilator for a 4 mm cylinder. The cylinder of tissue having a circumference about equal to the circumference of the expanded stent may be provided on the unexpanded stent in a folded or wrapped configuration. In one embodiment, the tissue on the unexpanded stent forms wings 30 on either side of the stent which are folded about stent, reducing the profile of the assembly, and unfolding upon expansion of the stent. In the embodiment illustrated in Fig. 5, the wings are folded in the same direction in an S-shaped configuration. In another embodiment, illustrated in Fig. 6, the wings of the cylinder of tissue on the unexpanded stent are folded about stent in opposite directions in a U-shaped configuration. However, the cylinder of tissue may be placed about the unexpanded stent in a variety of suitable configurations, as for example, where the wings of the cylinder of tissue are collapsed toward the stent, such as in an accordion type configuration (not shown). It would be apparent to one of skill in the art that the heterologous tissue forming the jacket could be folded about the unexpanded stent as outlined above whether or not the tissue had been formed into a cylinder of tissue before mounting onto the unexpanded stent. In another embodiment, the heterologous tissue is wrapped around the unexpanded stent, so that sufficient tissue to cover the expanded stent is provided. In one embodiment, illustrated in Fig. 7, a ribbon of tissue is spirally wrapped around the unexpanded stent down a length thereof. The adjacent turns of the ribbon of tissue overlap, so that the ribbon unwraps as the stent expands to provide the jacket 1 4 configured to cover the expanded stent and having a circumference about equal to the circumference of the expanded stent. Preferably, the ribbon of tissue is wrapped along the entire length of the stent. In another embodiment, a rectangle of tissue having a width about equal to the circumference of the expanded stent on which it is to be mounted is repeatably wrapped around the outer circumference of the unexpanded stent, so that multiple layers of tissue are present on at least a part of the unexpanded stent, as shown in Fig. 8, illustrating a transverse cross section of an unexpanded stent with a wrapped jacket thereon. Preferably, one end of the tissue is fixed to the stent, and the tissue is then tightly wrapped around the stent. Upon expansion of the stent, the tissue unwraps to provide the jacket 14 having a circumference about equal to the circumference of the expanded stent. Preferably the length of the tissue is about equal to the length of the stent. The tissue can be caused to remain in the folded or wrapped configurations until the stent is expanded by pressing the fluid out of the folded or wrapped tissue. Additionally, securing members such as surgical tape, ties, or breakable bands may be provided to releasably hold the tissue in the folded or wrapped configurations.
Depending upon the jacket material, the tissue may be kept wet at all times during manipulation or it may be dry until advanced into the patient's blood stream. Additionally, radio-opaque markers, such as rings of gold or platinum, may be added to the outer layer of the tissue so that the integrity of the cylinder may be assured before deployment within the body lumen. The cylinder of heterologous tissue configured to be mounted onto a stent and the jacket 14 formed by the cylinder of tissue or the unwrapped or unfolded tissue generally has a length, for coronary applications, of about 4 to greater than about 80 mm, typically about 5 to about 80 mm, preferably about 1 0 to about 50 mm, and a diameter of about 1 .5 to about 35 mm, typically about 2 to about 6 mm, preferably about 2.5 to about 5 mm. The actual length and diameter of the cylinder of heterologous tissue may vary, and will depend on the nature of the vessel in which the stent assembly is implanted. For example, for peripheral vessel applications, such as an aortic abdominal aneurysm, a larger cylinder of heterologous tissue having a length of about 5 mm to about 200 mm and a diameter of about 2 mm to about 60 mm would be used.
The jacketed stent assembly 10 is inserted into the body lumen in the following fashion. A guidewire 20 is backloaded into a delivery catheter 22 having the jacketed stent assembly 1 0 mounted over an inflatable balloon 24 on the distal extremity of the delivery catheter (as schematically shown in Fig. 2) or on a self expanding stent delivery system (not shown). The catheter 22 and guidewire 20 are percutaneously introduced by means of a conventional Seldinger technique and a 5^9 or 1 0 French guiding catheter (not shown) into the patient's arterial system. Larger guiding catheters, for example up to about 25 Fr, may be used depending on the application. The guidewire 20 is advanced out delivery catheter 22 through the vasculature under fluoroscopic imaging until it crosses a stenotic region. Then the catheter 22 is advanced over the guidewire 20 until the stent assembly 10 is positioned at the desired location within the stenotic region. Then, the balloon 24 is inflated or the securing mechanism of the self expanding stent is released to expand the stent 1 2 and cylindrical jacket 1 4, seating the assembly 1 0 within the vessel. The balloon 24 is then deflated and the catheter 22 is removed, leaving the expanded stent assembly 10 in place. Although primarily described with respect to preventing restenosis in angioplasty patients, the covered stents of this invention may be used in a number of coronary artery, peripheral artery and non-vascular applications. For example, coronary artery applications include use in ectatic arteries and ectatic arteries containing an obstructive lesion, aneurismatic arteries, saphenous vein grafts and native arteries, coronary perforation, coronary fistula, and ostial coronary lesions. Peripheral artery applications include aortic abdominal aneurysm and other aneurismatic peripheral arteries, transjugular intrahepatic portal shunt, percutaneous transluminal angioplasty, fistula closing and neuro interventions (such as aneurysms and arterial-venous malformations), small vessel intraluminal grafting, and ostial renal artery lesions. Finally, the covered stents of this invention may be used in urological, gastroenterological, respiratory, neurological, and other non-vascular applications. For example, urological field applications include urethral stenting for stenosis due to tumors, fibrous tissue and perforation. Gastroenterological field applications include fistula closing, reconstruction such as esophagus reconstruction, and esophageal bleeding. Respiratory field applications include tracheal and bronchial obstructions, and neurological field applications include carotid angioplasty.
A general description of the device of the present invention as well as a preferred embodiment of the present invention has been set forth above. One skilled in the art will recognize and be able to practice many changes in many aspects of the device described above, including variations that fall within the teachings of this invention. For example, the assembly may include a second expandable stent, so that the heterologous tissue layer is between two coaxially disposed stents. Additionally, the jacket may cover the entire stent or only a portion thereof. Additionally, the stent assembly may be used in branched body lumens, and positioned to block one or more of the branch lumens. The spirit and scope of the invention should be limited only as set forth in the claims which follow.

Claims

WHAT IS CLAIMED IS:
1 . A stent assembly for maintaining the patency of a body lumen comprising an expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic material.
2. The stent assembly of claim 1 wherein the cylindrical jacket is formed of heterologous tissue.
3. The stent of claim 2, wherein the heterologous tissue is selected from the group consisting of bovine pericardium, porcine pericardium, and aortic leaflet, veins and arteries.
4. The stent of claim 3, wherein the heterologous tissue comprises bovine pericardium with cross-linked collagen.
5. The stent of claim 2 including at least one therapeutic or diagnostic agent releasably contained in the cylindrical jacket.
6. The stent assembly of claim 1 wherein the material is expandable.
7. The stent assembly of claim 1 wherein the stent comprises a metallic tubular member.
8. The stent assembly of claim 1 wherein the cylindrical jacket is on an exterior surface of the stent.
9. The stent assembly of claim 1 wherein the stent is disposed within the cylindrical jacket.
1 0. A method for maintaining the patency of a body lumen comprising the steps of: a) mounting on a delivery catheter a stent assembly comprising a tubular expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material; b) advancing the delivery catheter through the body lumen until the stent assembly is positioned at a desired location; c) expanding the stent assembly to anchor it within the bodily lumen; and d) withdrawing the delivery catheter.
1 1 . A cylindrical jacket formed of heterologous tissue configured to fit over a portion of an intraluminal stent.
1 2. The cylindrical jacket of claim 1 1 having a length of about 4 to about 200 mm.
1 3. The cylindrical jacket of claim 1 1 having a length of about 1 0 to about 50 mm.
1 4. The cylindrical jacket of claim 1 1 having a diameter of about 1 .5 to about 60 mm.
1 5. The cylindrical jacket of claim 1 4 having a diameter of not greater than about 6 mm.
1 6. The cylindrical jacket of claim 1 1 having a diameter of about 2.5 to about 5 mm.
1 7. The cylindrical jacket of claim 1 1 having a thickness of about 0.05 mm to about 0.20 mm.
1 8. The cylindrical jacket of claim 1 1 having a thickness of about
0.1 mm to about 0.1 5 mm.
1 9. The cylindrical jacket of claim 1 1 configured to fit over an outer portion of the intraluminal stent.
20. The cylindrical jacket of claim 1 1 configured to cover an inner portion of the intraluminal stent.
21 . A method of treating a patient, comprising: a) providing an elongated delivery catheter having an expandable member on a distal extremity thereof; b) mounting an expandable stent having a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material onto the expandable member on the distal extremity of the delivery catheter; c) advancing at least the distal extremity of the catheter within a body lumen of the patient until the jacketed stent is disposed at a desired location within the body lumen; d) expanding the expandable member on the distal extremity of the catheter to expand the jacketed stent mounted thereon and fix the expanded jacketed stent within the body lumen; and e) contracting the expanded expandable member so the elongated delivery catheter can be removed from the patient.
22. A stent assembly for maintaining the patency of a body lumen comprising an expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material containing a therapeutic or diagnostic agent.
23. The stent assembly of claim 22 wherein the therapeutic agent is selected from the group consisting of antithrombotic agents and angiogenesis agents.
24. The stent assembly of claim 23 wherein the antithrombotic agent is selected from the group consisting of is selected from the group consisting of heparin, urokinase, streptokinase, tissue plasminogen activator, and abciximab, and the angiogenesis agent is selected from the group consisting of Fibroblast Growth Factor and Vascular Endothelial Growth Factor.
25. The stent assembly of claim 22 wherein material comprises heterologous tissue configured to fit over at least one of an outer surface and an inner surface of the stent.
26. A method for maintaining the patency of a body lumen comprising the steps of: a) mounting on a delivery catheter a stent assembly comprising a tubular expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material containing a therapeutic or diagnostic agent; b) advancing the delivery catheter through the body lumen until the stent assembly is positioned at a desired location; c) expanding the stent assembly to anchor it within the bodily lumen and deliver the therapeutic or diagnostic agent to the desired location within the body lumen; and d) withdrawing the delivery catheter.
27. The method of claim 26 wherein the delivery catheter has an expandable member on a distal extremity thereof, and including the step of mounting the expandable stent onto the delivery catheter expandable member, and wherein the step of expanding the stent comprises expanding the delivery catheter expandable member.
28. The method of claim 26 including the step of contracting the expanded expandable member so the delivery catheter can be removed from the patient.
29. An expandable jacketed stent comprising a metallic tubular member configured to expand from a first circumference configuration to a second circumference configuration, and a jacket formed of heterologous tissue containing a therapeutic or diagnostic agent and having a thickness of about 0.05 mm to about 0.20 mm.
30. The jacketed stent of claim 29 wherein the jacket is on an outer surface of the stent in a folded configuration configured to unfold as the stent expands to the second circumference configuration.
31 . The jacketed stent of claim 29 wherein the jacket is on an outer surface of the stent in a wrapped configuration configured to unwrap as the stent expands to the second circumference configuration.
32. A method of treating a patient, comprising: a) providing an elongated delivery catheter having an expandable member on a distal extremity thereof; b) mounting onto the expandable member on the distal extremity of the delivery catheter an expandable stent having first circumference and a second expanded circumference and having a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material on an outer surface of the stent, the jacket having a width about equal to the second expanded circumference of the stent; c) advancing at least the distal extremity of the catheter within a body lumen of the patient until the jacketed stent is disposed at a desired location within the body lumen; d) expanding the expandable member on the distal extremity of the catheter to expand the jacketed stent mounted thereon and fix the expanded jacketed stent within the body lumen; and e) contracting the expanded expandable member so the elongated delivery catheter can be removed from the patient.
33. The method of claim 32 wherein the jacket is in a folded configuration configured to unfold as the stent expands to the second circumference configuration.
34. The method of claim 32 wherein the jacket is in a wrapped configuration configured to unwrap as the stent expands to the second circumference configuration.
PCT/IB1998/001459 1997-09-23 1998-09-21 Non-thrombogenic stent jacket WO1999015105A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000512482A JP2003526380A (en) 1997-09-23 1998-09-21 Non-thrombogenic stent jacket
AU90911/98A AU749285B2 (en) 1997-09-23 1998-09-21 Non-thrombogenic stent jacket
CA002304495A CA2304495C (en) 1997-09-23 1998-09-21 Non-thrombogenic stent jacket
DE69840652T DE69840652D1 (en) 1997-09-23 1998-09-21 NOT THROMBOGEN STENT COAT
ES98942952T ES2323741T3 (en) 1997-09-23 1998-09-21 COVER FOR NON-THROMBOGENIC CANULA.
EP98942952A EP1017335B1 (en) 1997-09-23 1998-09-21 Non-thrombogenic stent jacket

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US08/935,784 US6468300B1 (en) 1997-09-23 1997-09-23 Stent covered heterologous tissue
US08/935,784 1997-09-23
US597298A 1998-01-12 1998-01-12
US09/005,972 1998-01-12
US3511498A 1998-03-04 1998-03-04
US09/035,114 1998-03-04
US5320098A 1998-04-01 1998-04-01
US09/053,200 1998-04-01
US09/156,034 US6254627B1 (en) 1997-09-23 1998-09-17 Non-thrombogenic stent jacket
US09/156,034 1998-09-17

Publications (1)

Publication Number Publication Date
WO1999015105A1 true WO1999015105A1 (en) 1999-04-01

Family

ID=27533145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001459 WO1999015105A1 (en) 1997-09-23 1998-09-21 Non-thrombogenic stent jacket

Country Status (10)

Country Link
US (3) US6254627B1 (en)
EP (1) EP1017335B1 (en)
JP (1) JP2003526380A (en)
CN (1) CN1290152A (en)
AT (1) ATE424786T1 (en)
AU (1) AU749285B2 (en)
CA (1) CA2304495C (en)
DE (1) DE69840652D1 (en)
ES (1) ES2323741T3 (en)
WO (1) WO1999015105A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138278A1 (en) * 2000-03-22 2001-10-04 Zuli Holdings Ltd. Method and apparatus for covering a stent
WO2002022024A3 (en) * 2000-09-12 2003-01-30 Advanced Cardiovascular System Stent with overlapping cover
GB2393660A (en) * 2000-03-22 2004-04-07 Zuli Holdings Ltd Covered stents
JP2005525909A (en) * 2002-05-22 2005-09-02 ボストン サイエンティフィック リミテッド Segmental graft embedded stent
US11517371B2 (en) 2018-06-11 2022-12-06 Boston Scientific Scimed, Inc. Sphincterotomes and methods for using sphincterotomes
US11944557B2 (en) 2020-08-31 2024-04-02 Boston Scientific Scimed, Inc. Self expanding stent with covering

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254627B1 (en) * 1997-09-23 2001-07-03 Diseno Y Desarrollo Medico S.A. De C.V. Non-thrombogenic stent jacket
US6146389A (en) * 1998-04-23 2000-11-14 Boston Scientific Corporation Stent deployment device and method for deploying a stent
US20020081732A1 (en) * 2000-10-18 2002-06-27 Bowlin Gary L. Electroprocessing in drug delivery and cell encapsulation
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20040018226A1 (en) * 1999-02-25 2004-01-29 Wnek Gary E. Electroprocessing of materials useful in drug delivery and cell encapsulation
US6592623B1 (en) 1999-08-31 2003-07-15 Virginia Commonwealth University Intellectual Property Foundation Engineered muscle
US6264671B1 (en) * 1999-11-15 2001-07-24 Advanced Cardiovascular Systems, Inc. Stent delivery catheter and method of use
US20060069423A1 (en) * 1999-11-22 2006-03-30 Fischell David R Means and method for treating an intimal dissection after stent implantation
US7011673B2 (en) * 1999-11-22 2006-03-14 Fischell Robert E Stent delivery system with a fixed guide wire
US6936065B2 (en) * 1999-11-22 2005-08-30 Cordis Corporation Stent delivery system having a fixed guidewire
US6929658B1 (en) * 2000-03-09 2005-08-16 Design & Performance-Cyprus Limited Stent with cover connectors
EP1267748B1 (en) * 2000-03-09 2006-06-28 Design & Performance - Cyprus Limited Stent with cover connectors
US6613082B2 (en) * 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US6953476B1 (en) * 2000-03-27 2005-10-11 Neovasc Medical Ltd. Device and method for treating ischemic heart disease
IL153753A0 (en) * 2002-12-30 2003-07-06 Neovasc Medical Ltd Varying-diameter vascular implant and balloon
US6680126B1 (en) * 2000-04-27 2004-01-20 Applied Thin Films, Inc. Highly anisotropic ceramic thermal barrier coating materials and related composites
CA2457162A1 (en) * 2000-09-01 2002-03-07 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed fibrin-based matrices and tissues
US6911038B2 (en) * 2001-05-08 2005-06-28 Scimed Life Systems, Inc. Matched balloon to stent shortening
CA2462509A1 (en) 2001-10-04 2003-04-10 Neovasc Medical Ltd. Flow reducing implant
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US20060106449A1 (en) * 2002-08-08 2006-05-18 Neovasc Medical Ltd. Flow reducing implant
EP1534180A4 (en) * 2002-08-08 2007-04-04 Neovasc Medical Ltd Geometric flow regulator
US7550004B2 (en) * 2002-08-20 2009-06-23 Cook Biotech Incorporated Endoluminal device with extracellular matrix material and methods
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US9254213B2 (en) * 2004-01-09 2016-02-09 Rubicon Medical, Inc. Stent delivery device
US20060095121A1 (en) * 2004-10-28 2006-05-04 Medtronic Vascular, Inc. Autologous platelet gel on a stent graft
US8961586B2 (en) * 2005-05-24 2015-02-24 Inspiremd Ltd. Bifurcated stent assemblies
US8043323B2 (en) 2006-10-18 2011-10-25 Inspiremd Ltd. In vivo filter assembly
CA2843097C (en) 2005-05-24 2015-10-27 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
CA2625264C (en) 2005-10-13 2015-12-15 Synthes (U.S.A.) Drug-impregnated sleeve for a medical implant
US20070106368A1 (en) * 2005-11-07 2007-05-10 Carlos Vonderwalde Graft-stent assembly
US20070106375A1 (en) * 2005-11-07 2007-05-10 Carlos Vonderwalde Bifurcated stent assembly
US20080215076A1 (en) * 2005-11-14 2008-09-04 Sentinel Group, Llc Gastro-intestinal therapeutic device and method
US20090069880A1 (en) * 2006-02-03 2009-03-12 Design & Performance - Cyprus Limited Implantable graft assembly and aneurysm treatment
US8425584B2 (en) * 2006-04-21 2013-04-23 W. L. Gore & Associates, Inc. Expandable covered stent with wide range of wrinkle-free deployed diameters
US8721704B2 (en) * 2006-04-21 2014-05-13 W. L. Gore & Associates, Inc. Expandable stent with wrinkle-free elastomeric cover
AU2007272601B2 (en) 2006-07-10 2014-01-16 First Quality Hygienic, Inc. Resilient device
US8613698B2 (en) 2006-07-10 2013-12-24 Mcneil-Ppc, Inc. Resilient device
US10219884B2 (en) 2006-07-10 2019-03-05 First Quality Hygienic, Inc. Resilient device
US8047980B2 (en) 2006-07-10 2011-11-01 Mcneil-Ppc, Inc. Method of treating urinary incontinence
US10004584B2 (en) 2006-07-10 2018-06-26 First Quality Hygienic, Inc. Resilient intravaginal device
WO2008047368A2 (en) * 2006-10-18 2008-04-24 Inspiremd Ltd. Filter assemblies
US20100324664A1 (en) * 2006-10-18 2010-12-23 Asher Holzer Bifurcated Stent Assemblies
CN102836023B (en) * 2006-10-18 2015-12-02 印斯拜尔Md有限公司 The support casing of braiding
CN101578078B (en) 2006-11-22 2013-01-02 印斯拜尔Md有限公司 Optimized stent jacket
WO2010059783A2 (en) * 2008-11-21 2010-05-27 Lifecell Corporation Reinforced biologic material
US20100262157A1 (en) * 2009-04-14 2010-10-14 Medtronic Vascular, Inc. Methods and Systems for Loading a Stent
WO2011079222A2 (en) 2009-12-23 2011-06-30 Boston Scientific Scimed, Inc. Less traumatic method of delivery of mesh-based devices into human body
AU2011213068A1 (en) * 2010-02-02 2012-08-16 Thoratec Llc Expandable and collapsible medical device
US20120130475A1 (en) * 2010-11-16 2012-05-24 Shaw Edward E Sleeves for expandable medical devices
WO2012109309A2 (en) 2011-02-09 2012-08-16 Neograft Technologies, Inc. System and mandrel for creating graft devices
CN102462565B (en) * 2011-10-25 2014-03-26 张石江 Recyclable and adjustable interventional stent for constricting blood vessels
TWI590843B (en) 2011-12-28 2017-07-11 信迪思有限公司 Films and methods of manufacture
EP2944330A4 (en) * 2013-01-08 2016-09-07 Chemo Sero Therapeut Res Inst Artificial blood vessel using decellularized blood vessel sheet
CN105555328B (en) 2013-06-21 2019-01-11 德普伊新特斯产品公司 film and manufacturing method
WO2015200906A1 (en) * 2014-06-27 2015-12-30 Boston Scientific Scimed, Inc. Compositions, devices, kits and methods for attaching stent-containing medical devices to tissue
CA2978401C (en) 2015-03-12 2022-04-12 The Chemo-Sero-Therapeutic Research Institute Anti-adhesion material and substitute biomembrane using decellularized tissue
US10413635B2 (en) * 2015-08-17 2019-09-17 Vivex Biomedical, Inc. Umbilical cord transplant product
US10456245B2 (en) * 2016-05-16 2019-10-29 Edwards Lifesciences Corporation System and method for applying material to a stent
JP7051299B2 (en) 2017-03-24 2022-04-11 ニプロ株式会社 Stent
CN108785754A (en) * 2017-05-05 2018-11-13 赛诺医疗科学技术股份有限公司 Medical overlay film frame
CN108720970A (en) * 2018-05-10 2018-11-02 广东省人民医院(广东省医学科学院) A kind of novel intratracheal fistula mouth holder
CN110833469B (en) * 2018-08-17 2023-06-20 先健科技(深圳)有限公司 Tectorial membrane support
RU187447U1 (en) * 2018-11-22 2019-03-06 Закрытое акционерное общество "НеоКор" (ЗАО "НеоКор") Biological prosthesis of arteries with an external mesh tubular coating of the external wall
JP7403547B2 (en) 2019-01-23 2023-12-22 ニオバスク メディカル リミテッド coated flow modifier

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015583A1 (en) * 1993-01-08 1994-07-21 Pdt Systems, Inc. Medicament dispensing stents
US5556414A (en) * 1995-03-08 1996-09-17 Wayne State University Composite intraluminal graft
US5575818A (en) * 1995-02-14 1996-11-19 Corvita Corporation Endovascular stent with locking ring
WO1997009006A1 (en) * 1995-09-01 1997-03-13 Emory University Endovascular support device and method of use
WO1997012563A1 (en) * 1995-10-03 1997-04-10 Malcolm Rawlings Method of covering a stent with acellular matrix
WO1997024081A1 (en) * 1995-12-29 1997-07-10 Ramus Medical Technologies Method and apparatus for forming vascular prostheses

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US450259A (en) * 1891-04-14 Warp-beamer
US4470157A (en) * 1981-04-27 1984-09-11 Love Jack W Tricuspid prosthetic tissue heart valve
US4400833A (en) 1981-06-10 1983-08-30 Kurland Kenneth Z Means and method of implanting bioprosthetics
US4502159A (en) 1982-08-12 1985-03-05 Shiley Incorporated Tubular prostheses prepared from pericardial tissue
US4477930A (en) * 1982-09-28 1984-10-23 Mitral Medical International, Inc. Natural tissue heat valve and method of making same
US4801299A (en) * 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5609626A (en) * 1989-05-31 1997-03-11 Baxter International Inc. Stent devices and support/restrictor assemblies for use in conjunction with prosthetic vascular grafts
US5578071A (en) 1990-06-11 1996-11-26 Parodi; Juan C. Aortic graft
US5163955A (en) * 1991-01-24 1992-11-17 Autogenics Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment
US5489298A (en) 1991-01-24 1996-02-06 Autogenics Rapid assembly concentric mating stent, tissue heart valve with enhanced clamping and tissue exposure
US5304220A (en) * 1991-07-03 1994-04-19 Maginot Thomas J Method and apparatus for implanting a graft prosthesis in the body of a patient
US5376376A (en) 1992-01-13 1994-12-27 Li; Shu-Tung Resorbable vascular wound dressings
US5489297A (en) * 1992-01-27 1996-02-06 Duran; Carlos M. G. Bioprosthetic heart valve with absorbable stent
JPH07505803A (en) 1992-04-21 1995-06-29 バクスター インターナショナル インコーポレーテッド Stent appliances and support/restrictor assemblies for use with prosthetic vascular grafts
US5383928A (en) 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
BE1006440A3 (en) 1992-12-21 1994-08-30 Dereume Jean Pierre Georges Em Luminal endoprosthesis AND METHOD OF PREPARATION.
US5599307A (en) 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
US5632772A (en) 1993-10-21 1997-05-27 Corvita Corporation Expandable supportive branched endoluminal grafts
US5723004A (en) 1993-10-21 1998-03-03 Corvita Corporation Expandable supportive endoluminal grafts
US5443497A (en) * 1993-11-22 1995-08-22 The Johns Hopkins University Percutaneous prosthetic by-pass graft and method of use
US5549663A (en) 1994-03-09 1996-08-27 Cordis Corporation Endoprosthesis having graft member and exposed welded end junctions, method and procedure
CA2188563C (en) 1994-04-29 2005-08-02 Andrew W. Buirge Stent with collagen
US5584876A (en) 1994-04-29 1996-12-17 W. L. Gore & Associates, Inc. Cell excluding sheath for vascular grafts
US5653743A (en) 1994-09-09 1997-08-05 Martin; Eric C. Hypogastric artery bifurcation graft and method of implantation
US5674298A (en) 1994-10-21 1997-10-07 The Board Of Regents Of The University Of Michigan Calcification-resistant bioprosthetic tissue and methods of making same
CA2175720C (en) * 1996-05-03 2011-11-29 Ian M. Penn Bifurcated stent and method for the manufacture and delivery of same
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5641373A (en) 1995-04-17 1997-06-24 Baxter International Inc. Method of manufacturing a radially-enlargeable PTFE tape-reinforced vascular graft
US5667523A (en) 1995-04-28 1997-09-16 Impra, Inc. Dual supported intraluminal graft
FR2733682B1 (en) * 1995-05-04 1997-10-31 Dibie Alain ENDOPROSTHESIS FOR THE TREATMENT OF STENOSIS ON BIFURCATIONS OF BLOOD VESSELS AND LAYING EQUIPMENT THEREFOR
US5628786A (en) 1995-05-12 1997-05-13 Impra, Inc. Radially expandable vascular graft with resistance to longitudinal compression and method of making same
US5669924A (en) * 1995-10-26 1997-09-23 Shaknovich; Alexander Y-shuttle stent assembly for bifurcating vessels and method of using the same
JPH09122225A (en) * 1995-10-31 1997-05-13 Bio Eng Lab:Kk Raw membrane material for medical material and manufacture thereof
US6017363A (en) * 1997-09-22 2000-01-25 Cordis Corporation Bifurcated axially flexible stent
UA58485C2 (en) * 1996-05-03 2003-08-15 Медінол Лтд. Method for manufacture of bifurcated stent (variants) and bifurcated stent (variants)
EP0844853B1 (en) 1996-05-31 2003-12-17 Ave Galway Limited Bifurcated endovascular stents
US5617878A (en) * 1996-05-31 1997-04-08 Taheri; Syde A. Stent and method for treatment of aortic occlusive disease
US5755773A (en) 1996-06-04 1998-05-26 Medtronic, Inc. Endoluminal prosthetic bifurcation shunt
FR2749500B1 (en) 1996-06-06 1998-11-20 Jacques Seguin DEVICE ALLOWING THE TREATMENT OF BODY DUCTS AT THE LEVEL OF A BIFURCATION
US5741326A (en) * 1996-07-15 1998-04-21 Cordis Corporation Low profile thermally set wrapped cover for a percutaneously deployed stent
US5676697A (en) * 1996-07-29 1997-10-14 Cardiovascular Dynamics, Inc. Two-piece, bifurcated intraluminal graft for repair of aneurysm
US5755778A (en) * 1996-10-16 1998-05-26 Nitinol Medical Technologies, Inc. Anastomosis device
US6086610A (en) 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
EP0944366B1 (en) * 1996-11-04 2006-09-13 Advanced Stent Technologies, Inc. Extendible double stent
US5972017A (en) * 1997-04-23 1999-10-26 Vascular Science Inc. Method of installing tubular medical graft connectors
US5782914A (en) 1996-11-29 1998-07-21 Bio-Vascular, Inc. Method for preparing heterogeneous tissue grafts
JP4074666B2 (en) 1996-12-10 2008-04-09 クック バイオテック、インク. Tubular grafts from purified submucosa
US6302908B1 (en) * 1997-03-24 2001-10-16 Juan Carlos Parodi Arterial graft device and method of positioning the same
US5934283A (en) * 1997-04-15 1999-08-10 Uroplasty, Inc. Pubovaginal sling device
US5984955A (en) * 1997-09-11 1999-11-16 Wisselink; Willem System and method for endoluminal grafting of bifurcated or branched vessels
US6468300B1 (en) * 1997-09-23 2002-10-22 Diseno Y Desarrollo Medico, S.A. De C.V. Stent covered heterologous tissue
US6254627B1 (en) * 1997-09-23 2001-07-03 Diseno Y Desarrollo Medico S.A. De C.V. Non-thrombogenic stent jacket
US5980565A (en) * 1997-10-20 1999-11-09 Iowa-India Investments Company Limited Sandwich stent
US6117166A (en) * 1997-10-27 2000-09-12 Winston; Thomas R. Apparatus and methods for grafting blood vessel tissue
US5961548A (en) * 1997-11-18 1999-10-05 Shmulewitz; Ascher Bifurcated two-part graft and methods of implantation
CA2324958C (en) * 1998-03-23 2009-12-22 Bio-Vascular, Inc. Pericardial tissue implants and methods of making them
US20020123789A1 (en) * 1998-12-04 2002-09-05 Francis Ralph T. Stent cover
US6432712B1 (en) * 1999-11-22 2002-08-13 Bioscience Consultants, Llc Transplantable recellularized and reendothelialized vascular tissue graft
US6378221B1 (en) * 2000-02-29 2002-04-30 Edwards Lifesciences Corporation Systems and methods for mapping and marking the thickness of bioprosthetic sheet
US6929658B1 (en) * 2000-03-09 2005-08-16 Design & Performance-Cyprus Limited Stent with cover connectors
US7547322B2 (en) * 2001-07-19 2009-06-16 The Cleveland Clinic Foundation Prosthetic valve and method for making same
US6579307B2 (en) * 2001-07-19 2003-06-17 The Cleveland Clinic Foundation Endovascular prosthesis having a layer of biological tissue
US20060136047A1 (en) * 2002-09-06 2006-06-22 Obermiller F J Tissue graft prosthesis devices containing juvenile or small diameter submucosa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015583A1 (en) * 1993-01-08 1994-07-21 Pdt Systems, Inc. Medicament dispensing stents
US5575818A (en) * 1995-02-14 1996-11-19 Corvita Corporation Endovascular stent with locking ring
US5556414A (en) * 1995-03-08 1996-09-17 Wayne State University Composite intraluminal graft
WO1997009006A1 (en) * 1995-09-01 1997-03-13 Emory University Endovascular support device and method of use
WO1997012563A1 (en) * 1995-10-03 1997-04-10 Malcolm Rawlings Method of covering a stent with acellular matrix
WO1997024081A1 (en) * 1995-12-29 1997-07-10 Ramus Medical Technologies Method and apparatus for forming vascular prostheses

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106376B4 (en) * 2000-03-22 2005-08-04 Zuli Holdings Ltd. Method of sheathing an intraluminal stent and intraluminal stent coated in this manner
US6736838B1 (en) 2000-03-22 2004-05-18 Zuli Holdings Ltd. Method and apparatus for covering a stent
US7384428B2 (en) 2000-03-22 2008-06-10 Medinol, Ltd. Method and apparatus for covering a stent
AU767745B2 (en) * 2000-03-22 2003-11-20 Medinol Ltd Method and apparatus for covering a stent
EP1138278A1 (en) * 2000-03-22 2001-10-04 Zuli Holdings Ltd. Method and apparatus for covering a stent
GB2393660A (en) * 2000-03-22 2004-04-07 Zuli Holdings Ltd Covered stents
SG85225A1 (en) * 2000-03-22 2001-12-19 Zuli Holdings Ltd Method and apparatus for covering a stent
GB2393660B (en) * 2000-03-22 2004-05-26 Zuli Holdings Ltd Covered stents
GB2362107B (en) * 2000-03-22 2004-03-10 Zuli Holdings Ltd Covered stents
US7118592B1 (en) 2000-09-12 2006-10-10 Advanced Cardiovascular Systems, Inc. Covered stent assembly for reduced-shortening during stent expansion
WO2002022024A3 (en) * 2000-09-12 2003-01-30 Advanced Cardiovascular System Stent with overlapping cover
JP2005525909A (en) * 2002-05-22 2005-09-02 ボストン サイエンティフィック リミテッド Segmental graft embedded stent
US7887575B2 (en) 2002-05-22 2011-02-15 Boston Scientific Scimed, Inc. Stent with segmented graft
US8197533B2 (en) 2002-05-22 2012-06-12 Dennis Kujawski Stent with segmented graft
US11517371B2 (en) 2018-06-11 2022-12-06 Boston Scientific Scimed, Inc. Sphincterotomes and methods for using sphincterotomes
US11944557B2 (en) 2020-08-31 2024-04-02 Boston Scientific Scimed, Inc. Self expanding stent with covering

Also Published As

Publication number Publication date
CN1290152A (en) 2001-04-04
DE69840652D1 (en) 2009-04-23
US8882822B2 (en) 2014-11-11
CA2304495C (en) 2008-01-15
US6254627B1 (en) 2001-07-03
AU749285B2 (en) 2002-06-20
US20150032199A1 (en) 2015-01-29
ATE424786T1 (en) 2009-03-15
AU9091198A (en) 1999-04-12
US20050251244A1 (en) 2005-11-10
EP1017335A1 (en) 2000-07-12
CA2304495A1 (en) 1999-04-01
EP1017335B1 (en) 2009-03-11
JP2003526380A (en) 2003-09-09
ES2323741T3 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
CA2304495C (en) Non-thrombogenic stent jacket
US7108717B2 (en) Stent covered with heterologous tissue
US6565600B2 (en) Articulated expandable intraluminal stent
CA1281504C (en) Expandable intraluminal graft, and apparatus for implanting an expandable intraluminal graft
EP1621160B1 (en) Low deployment force delivery device
EP1061985B1 (en) Delivery system for deployment and endovascular assembly of multi-stage stent graft
JP3442081B2 (en) Inflatable bifurcated support lumen implant
JP2680901B2 (en) Extendable endoluminal implant
EP0874602B1 (en) Composite intraluminal graft
US5861025A (en) Tubular expandable member for an intraluminal endoprosthesis, intraluminal endoprosthesis, and method of production
JPH11347133A (en) Endoluminal supporting assembly with end cap
WO2001066037A2 (en) Intraluminal prosthesis
AU780149B2 (en) Non-thrombogenic stent jacket
WO1999015104A1 (en) Non-thrombogenic stent jacket

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809335.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998942952

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2304495

Country of ref document: CA

Ref document number: 2304495

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 90911/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998942952

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 90911/98

Country of ref document: AU